Aspect Biosystems

Vancouver-based Aspect Biosystems has secured $79 million in federal funding toward a $280 million project to advance its 3D-printed tissue therapies. Supported through the Strategic Response Fund, the initiative will enhance clinical development and expand biomanufacturing capabilities for cellular medicines.

Aspect, a University of British Columbia spinout, develops bioprinted tissues using living cells and biomaterials to repair damaged organs. The company will contribute the remaining $201 million. Chief executive Tamer Mohamed said the investment supports its transition toward clinical-stage development. The project builds on prior public and private funding, including partnerships with Novo Nordisk.

Want to know more? Check out the source code on Techcouver.com.

Vancouver-based Aspect Biosystems and Novo Nordisk have expanded their partnership to accelerate the development of advanced cellular medicines for diabetes. Building on a collaboration launched in 2023, the new agreement gives Aspect rights to key stem cell–derived islet and hypoimmune cell engineering technologies, with Aspect leading development, manufacturing, and commercialization.

Novo Nordisk will make an additional equity investment, provide research funding, and retain options for later-stage participation, as well as eligibility for milestones and royalties. The partnership integrates U.S. and Danish capabilities into Aspect’s Canada-anchored platform, strengthening its end-to-end cell therapy development efforts.

Want to know more? Check out the source code on Techcouver.com.

Vancouver’s Aspect Biosystems has raised USD $115 million in Series B funding, advancing its work on bioprinted tissue therapeutics. Led by Dimension and supported by Novo Nordisk, Radical Ventures, InBC, and others, the funding will expand Aspect’s AI-powered bioprinting and therapeutic platform.

The company aims to deliver cellular medicines for metabolic and endocrine diseases, building on partnerships with Novo Nordisk and Canadian governments. CEO Tamer Mohamed lauded the investor support, while Dimension’s Nan Li called Aspect a leader in regenerative medicine. This milestone cements Aspect’s role in biotech innovation and its pursuit of transformative patient care solutions.

Want to know more? Check out the source code on Techcouver.

Vancouver’s Aspect Biosystems announced a $72.75 million investment from the Governments of Canada and British Columbia to support a $200 million project advancing their bioprinted tissue therapeutics. This funding will enhance Aspect’s biomanufacturing capabilities and therapeutic platform, targeting incurable diseases with innovative treatments.

Aspect’s collaboration with Novo Nordisk will be leveraged, focusing on diabetes, obesity, liver disease, and other metabolic disorders. CEO Tamer Mohamed emphasized the investment as a crucial step in regenerative medicine.

Want to know more? Check out the source code on Techcouver.